Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2023.2176846
Abstract: ABSTRACT Introduction Cholangiocarcinoma (CCA) is an uncommon malignancy originating from epithelial cells of the biliary tract. Regardless of the site of origin within the biliary tree, CCAs are generally aggressive with a poor survival. Surgical… read more here.
Keywords: inhibitors cholangiocarcinoma; therapy; idh inhibitors; therapy developments ... See more keywords
Targeting STAT5 signaling overcomes resistance to IDH inhibitors in acute myeloid leukemia through suppression of stemness.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer research"
DOI: 10.1158/0008-5472.can-22-1293
Abstract: Mutant isocitrate dehydrogenase 1 (IDH1) and IDH2 block the differentiation of acute myeloid leukemia (AML) cells through production of R-2-hydroxyglutarate (R-2-HG). IDH inhibitors can induce differentiation of AML cells by lowering R-2-HG but have limited… read more here.
Keywords: myeloid leukemia; idh; acute myeloid; resistance ... See more keywords
IDH Inhibitors Target Common Mutation in Glioma.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nd2019-007
Abstract: Mutant-selective IDH1 inhibitors engage their target in the brain and shrink glioma tumors with an acceptable safety profile, according to phase I trial data on three different drug candidates. However, some clinicians argue the drug… read more here.
Keywords: target common; inhibitors target; glioma; mutation glioma ... See more keywords